GlassScriptPhysician profile
Ivan W Leung
NPI 1194341438
$3,792.94
in general payments reported to CMS, 2019-2025
11 companies · $1,193 in 2025
The $1,193 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $23.56 · 2023: $597 · 2024: $1,980 · 2025: $1,193.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,748 · Travel and Lodging: $21.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,747.51 |
| Travel and Lodging | $21.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,900.27 | 2023-2025 | Cabenuva, Dovato, Apretude |
| Gilead Sciences, INC. | $946.20 | 2023-2025 | Biktarvy |
| Emd Serono, INC. | $339.77 | 2023-2025 | Serostim, Serostim |
| Merck Sharp & Dohme LLC | $267.69 | 2023-2025 | Pifeltro, Delstrigo, Capvaxive |
| Lilly USA, LLC | $107.10 | 2023 | Mounjaro |
| Exact Sciences Corporation | $82.15 | 2023-2025 | Cologuard Collection Kit |
| Hologic Sales and Service, LLC | $46.98 | 2024-2025 | Aptima, Thinprep 2000 Processor |
| Napo Pharmaceuticals INC | $35.88 | 2023-2025 | Mytesi |
| Theratechnologies INC. | $27.65 | 2024 | Trogarzo, Egrifta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.56 | 2022 | |
| Abbvie INC. | $15.69 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ivan Leung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.